Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations.
Van Luan PhamNguyen Dinh TienNguyen Minh HaiNguyen Dao TienThi Thi DuyenPublished in: Therapeutic advances in medical oncology (2021)
This study conducted in Vietnam suggests the effectiveness of gefitinib as a first-line treatment option in patients with advanced NSCLC and positive EGFR mutations regardless of whether the patients have a good PS or not. In particular, targeted therapy with gefitinib improved the OS in women and non-smokers.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- small cell lung cancer
- tyrosine kinase
- end stage renal disease
- ejection fraction
- randomized controlled trial
- newly diagnosed
- chronic kidney disease
- systematic review
- brain metastases
- prognostic factors
- polycystic ovary syndrome
- smoking cessation
- peritoneal dialysis
- adipose tissue
- stem cells
- type diabetes
- pregnant women
- bone marrow
- mesenchymal stem cells
- pregnancy outcomes
- replacement therapy